Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia

PHASE3CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Hepatitis C Virus
Interventions
BIOLOGICAL

Pegylated-Interferon-lambda

DRUG

Ribavirin

DRUG

Daclatasvir

Trial Locations (32)

2050

Local Institution, Camperdown

3004

Local Institution, Melbourne

4029

Local Institution, Herston

Local Institution, Herston

5000

Local Institution, Adelaide

10126

Local Institution, Torino

19104

Hospital Of The University Of Pennsylvania, Philadelphia

20122

Local Institution, Milan

28046

Local Institution, Madrid

34295

Local Institution, Montpellier

38043

Local Institution, Grenoble

41013

Local Institution, Seville

50134

Local Institution, Florence

50524

Local Institution, Bucharest

54511

Local Institution, Vandœuvre-lès-Nancy

60612

Rush University Medical Center, Chicago

69317

Local Institution, Lyon

75651

Local Institution, Paris

75679

Local Institution, Paris

84123

Clinical Research Centers Of America, Murray

94304

Stanford Boswell Clinic, Palo Alto

107996

Local Institution, Moscow

191186

Local Institution, Saint Petersburg

700116

Local Institution, Iași

700506

Local Institution, Iași

900635

Local Institution, Constanța

00185

Local Institution, Roma

1105 AZ

Local Institution, Amsterdam

6525 GA

Local Institution, Nijmegen

3015 CE

Local Institution, Rotterdam

3508 GA

Local Institution, Utrecht

08035

Local Institution, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY